Central Nervous System Tumor

Interventional

Drug Intervention

IRB# STUDY00021117
PNOC 017: A Target Validation/Phase 1 Study of BGB-290 in Combination with Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas.

IRB# STUDY00021284
(Advarra-IRB) A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects with Residual or Recurrent Grade 2 Glioma with an IDH1 or IDH2 Mutation.

Surgical Intervention

IRB# STUDY00017499
An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults with Recurrent or Progressive Glioblastoma.

IRB# STUDY00021284
(Advarra-IRB) A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects with Residual or Recurrent Grade 2 Glioma with an IDH1 or IDH2 Mutation.

01 February 2021

http://www.ohsu.edu/research/rda/so/knight.php